Highest-materiality recent filing
AVITA Medical Q1 revenue $19.3M (+4% YoY); net loss narrows to $10.6M
Total revenue $19.3M, up 4% YoY and 10% sequentially, driven by Cohealyx and improved RECELL utilization.
AVITA Medical appoints Cary Vance as permanent CEO, Jan Stern Reed as Board Chair
Cary Vance named President and CEO effective April 30, 2026; served as Interim CEO since October 2025.
AVITA Medical Q4 revenue down 4% to $17.6M; FY2026 guidance $80-85M
Q4 revenue $17.6M (down 4% YoY); gross margin 81.2% vs 87.6%; net loss $11.6M ($0.38/sh) vs $11.6M ($0.44/sh).
AVITA Medical: Q4 rev ~$17.6M, FY2025 $71.6M; new $60M credit facility; FY2026 guidance $80-85M
Q4 2025 revenue ~$17.6M (vs $18.4M Q4 2024); Cohealyx-I fully enrolled, PermeaDerm-I >75% enrolled in Dec 2025.
AVITA Medical Q3 revenue falls 13% YoY to $17.1M; lowers FY2025 revenue guidance to $70-74M
Net loss improved to $13.2M ($0.46 loss per share) from $16.2M in Q3 2024; cash use cut to $6.2M.
AVITA Medical CEO departs, interim CEO appointed; Q3 preliminary revenue ~$17M
CEO Jim Corbett departed Oct 16, 2025; Chairman Cary Vance appointed Interim CEO effective immediately.
AVITA Medical raises ~$15M via placement of 17.2M CDIs at AU$1.32 each
Issued 17.2M CHESS Depositary Interests (CDIs) at AU$1.32/CDI; 5 CDIs = 1 common share.
Q2 2025 commercial revenue $18.4M (+21% YoY); net loss $9.9M vs $15.4M prior year.
AVITA Medical Q1 revenue $18.5M (+67% YoY); reaffirms FY guidance $100-106M
Net loss of $13.9M ($0.53/sh) improved from $18.7M loss ($0.73/sh) in Q1 2024.
AVITA Medical to manufacture PermeaDerm; revenue share rises to 60%
10-year contract manufacturing agreement for PermeaDerm at AVITA's Ventura, CA facility.
AVITA Medical Q4 revenue $18.4M (+30% YoY), net loss $11.6M; FY2025 guidance $100-106M
Q4 commercial revenue $18.4M (+30% YoY); gross margin 87.6%.
AVITA Medical slashes Q4 2024 revenue outlook to ~$18.4M; profitability pushed to Q4 2025
Q4 2024 commercial revenue expected ~$18.4M (30% YoY growth) vs prior guidance of $22.3-24.3M.
AVITA Medical Q3 revenue $19.5M (+44% YoY); amends OrbiMed debt, removes $50M tranches
Commercial revenue $19.5M, up 44% YoY; gross margin 83.7% vs 84.5%.
AVITA Medical Q2 commercial revenue record $15.1M (+29%); FY24 guide $68-70M
Commercial revenue $15.1M (+29% YoY); gross margin 86.2% (up 500 bps).
Exclusive 5-year deal for collagen-based dermal matrix; Regenity expects 510(k) clearance in Q4 2024.
AVITA Medical receives FDA approval for RECELL GO next-gen skin harvesting device
FDA approved RECELL GO next-gen autologous cell harvesting device for thermal burn wounds and full-thickness skin defects.
AVITA Medical Q1 revenue $11.1M (+5.8%), net loss $18.7M; lowers 2024 revenue guidance to lower end
Commercial revenue $11.1M, up 5.8% YoY; gross margin 86.4%.
the Board appointed Jan Stern Reed as Chair of the Board while simultaneously terminating the Lead Independent Director position that she had been serving since October 2025
the Board of Directors (the “Board”) of AVITA Medical, Inc (the "Company") appointed Cary Vance as President and Chief Executive Officer ("CEO"), effective April 30, 2026
On June 28, 2024, Ms. Donna Shiroma, the Company’s General Counsel, Compliance Officer and Corporate Secretary, notified AVITA Medical, Inc. (the "Company") of her retirement effective immediately.
Ms. Shiroma is succeeded by Nicole Kelsey, effective immediately, who will serve as the Company’s Chief Legal and Compliance Officer and Corporate Secretary.
Max materiality 0.85 · Median 0.68 · Most common event earnings